23rd Conference on Retroviruses and Opportunistic Infections (CROI 2016), 22-25 February 2016, Boston
1 June 2016. Related: Conference reports.
2016
No effect of tenofovir on infant bone mineral content in African study
1 June 2016. Related: Conference reports, Antiretrovirals, Pregnancy, Paediatric care.
Use of modelling to predicting paediatric dosing of long acting antiretrovirals
1 June 2016. Related: Conference reports, Antiretrovirals, Paediatric care, PK and drug interactions.
Nevirapine dosing for treatment of neonates
1 June 2016. Related: Conference reports, Paediatric care, PK and drug interactions.
START substudies: increased quality of life from earlier treatment but no impact on vascular function or cardiovascular markers
1 June 2016. Related: Conference reports, Antiretrovirals, Coinfections and complications.
Six-week ledipasvir/sofosbuvir in HIV positive patients with acute HCV
1 June 2016. Related: Conference reports, Hepatitis coinfection.
6th International Workshop on HIV & Women, 20-21 February 2016, Boston
1 June 2016. Related: Conference reports.
Doravirine can be co-administered with oral contraceptives
1 June 2016. Related: Conference reports, Women's health.
No increased risk of birth defects with darunavir: findings from the Antiretroviral Pregnancy Registry
1 June 2016. Related: Conference reports, Pregnancy.
FTC/TAF dual-nuke approved in the US and Europe
1 June 2016. Related: Antiretrovirals.
Paediatric labeling expanded, and additional tablet strengths for FTC/TDF
1 June 2016. Related: Antiretrovirals.
Timeline for access to generic dolutegravir: what still needs to be done
1 June 2016. Related: Treatment access.
Botswana “Treat All” programme will move to universal treatment with dolutegravir as first-line ART
1 June 2016. Related: Treatment access.
South Africa takes bold step to provide HIV treatment for all
1 June 2016. Related: Treatment access.
Persistent HPV infection may be related to tissue type in HIV positive people
1 June 2016. Related: Side effects.
Community reports
1 June 2016. Related: On the web.
May/June 2016: Volume 17 Number 5/6
1 June 2016. Related: PDFs.
March/April 2016: Volume 17 Number 3/4
22 March 2016. Related: Editorial.
23rd Conference on Retroviruses and Opportunistic Infections (CROI 2016), 22-25 February 2016, Boston
22 March 2016. Related: Conference reports.
Dual long-acting injections of cabotegravir plus rilpivirine: 32-week results from LATTE-2 study
22 March 2016. Related: Conference reports, Antiretrovirals.
New NRTI MK-8591 (EFdA): weekly oral dosing and once-yearly slow-release dosing has potential for HIV treatment and PrEP
22 March 2016. Related: Conference reports, Antiretrovirals.
Similar viral load reductions at week 4 when dolutegravir is used with 2- or 3-drug initial ART
22 March 2016. Related: Conference reports, Antiretrovirals.
48-week results for NNRTI doravirine compared to efavirenz
22 March 2016. Related: Conference reports, Antiretrovirals.
Dramatic increase in use of oral TDF/FTC for PrEP in the US – plus a few cautions
22 March 2016. Related: Conference reports, HIV prevention and transmission.
Future oral and long-acting formulations for PrEP: pills, films, gels, injections and depots
22 March 2016. Related: Conference reports, HIV prevention and transmission.
First data on TAF as PrEP to prevent HIV infection
22 March 2016. Related: Conference reports, HIV prevention and transmission.
Long-acting cabotegravir as PrEP protects macaques against IV exposure but will need two-monthly injections
22 March 2016. Related: Conference reports, HIV prevention and transmission.
Role for maraviroc as HIV PrEP likely to need dual combinations
22 March 2016. Related: Conference reports, HIV prevention and transmission.
Dapivirine PrEP vaginal ring shows only limited PrEP protection against HIV in African women
22 March 2016. Related: Conference reports, HIV prevention and transmission, Vaccines and microbicides.
Early data from dolutegravir use during pregnancy
22 March 2016. Related: Conference reports, Pregnancy.
Dolutegravir: 48 week results in children age 6 to 12 years old
22 March 2016. Related: Conference reports, Paediatric care.
New antiretrovirals could mean savings up to US $3 billion by 2025
22 March 2016. Related: Conference reports, Treatment access.
Countries with lower HIV prevalence have lower ART coverage
22 March 2016. Related: Conference reports, Antiretrovirals, Treatment access.
Nigerian herbal medicines widely used by HIV positive people can contain antiretrovirals
22 March 2016. Related: Conference reports, Antiretrovirals.
Cure research news from CROI 2016
22 March 2016. Related: Conference reports, Cure-related research.
EU adopts positive opinion on dual formulation of F/TAF
22 March 2016. Related: Antiretrovirals.
New TAF-containing fixed dose combination approved in the US
22 March 2016. Related: Antiretrovirals.
Community oppose dolutegravir and cabotegravir patents in India
22 March 2016. Related: Treatment access.
MSF call for cap for MDR-TB drug costs: only 180 people use delamanid over two years
22 March 2016. Related: Treatment access.
Global Fund provides Uganda with a year of drugs to meet shortages
22 March 2016. Related: Treatment access.
Transgender people left behind in the fight against HIV: Only 17 out of 130 countries have transgender representatives
22 March 2016. Related: Treatment access.
Mbeki shows no remorse for role in AIDS deaths
22 March 2016. Related: Treatment access.
Alcohol risks are higher in HIV positive people and linked to increased mortality
22 March 2016. Related: Side effects.
Canada approves TDF/FTC as PrEP
22 March 2016. Related: HIV prevention and transmission.
NHS England pulls proposed timeline for PrEP: perpetuates HIV health crisis in gay men and trans people
22 March 2016. Related: HIV prevention and transmission.
UK community campaign calls for NHS England to be accountable for PrEP timeline
22 March 2016. Related: HIV prevention and transmission.
HIV positive transplant donors approved in the US
22 March 2016. Related: Other news.
March/April 2016: Volume 17 Number 3/4
22 March 2016. Related: PDFs.
Jan/Feb 2016: Volume 17 Number 1/2
1 February 2016. Related: Editorial.
46th World Conference on Lung Health of the International Union Against TB and Lung Disease
1 February 2016. Related: Conference reports.
Promising first results with a 9-month regimen for multidrug resistant tuberculosis in French-speaking African countries
1 February 2016. Related: Conference reports, TB coinfection.
Pharmacokinetics of old and new TB drugs for children
1 February 2016. Related: Conference reports, PK and drug interactions, TB coinfection.
The REALITY trial: cotrimoxazole/isoniazid/pyridoxine tablets are bioequivalent to individual products and are acceptable to participants
1 February 2016. Related: Conference reports, TB coinfection.
BHIVA Autumn Conference 2015, 12-13 November 2015, London
1 February 2016. Related: Conference reports.
Selected webcasts from BHIVA Autumn conference 2015
1 February 2016. Related: Conference reports, On the web.
Treatment as Prevention (TasP) in the UK supports access to ART at any CD4 count
1 February 2016. Related: Treatment access.
WHO 2015 guidelines: newly recommended generic ART products on the way for adults
1 February 2016. Related: Treatment access.
Better generic ART for low and middle income countries: dolutegravir at US $44 a year
1 February 2016. Related: Treatment access.
When Global Fund support ends: Sustainability lessons from transitions in Costa Rica, Fiji, Romania, and Bulgaria
1 February 2016. Related: Treatment access.
BMS sells pipeline compounds to ViiV Healthcare
1 February 2016. Related: Antiretrovirals.
EU provide positive approval for generic lopinavir/ritonavir
1 February 2016. Related: Antiretrovirals.
Further results using dolutegravir monotherapy: urgent need for controlled studies
1 February 2016. Related: Antiretrovirals, Treatment strategies.
Potential economic impact of dolutegravir/3TC dual therapy
1 February 2016. Related: Antiretrovirals, Treatment strategies.
Renal monitoring in people living with HIV: a new review
1 February 2016. Related: Side effects.
New US guidelines strengthen recommendation for ART irrespective of CD4 count (January 2016)
1 February 2016. Related: Guidelines.